BiologIC Technologies

Precision LNPs: small scale bioreactors in downstream processing While installing a new system at a customer site recently, I reflected on the important role small scale precision bioreactors are now playing in the production of complex vesicles like lipid nanoparticles (LNPs), which are essential to the delivery of mRNA vaccines and gene therapies. LNPs are now established as the backbone of mRNA medicines, and many new biologic modalities are rapidly advancing whose targeted delivery will use established and new chemistries combined with ranges of therapeutic payloads. Small scale precision bioreactors are displacing own-built stirrer setups to help researchers develop better formulations faster. Precision bioreactors must be durable for chemical resistance and configurable in terms of setup. They must provide precise control of mixing dynamics, temperature, titration timing and speeds and other formulation conditions to create consistent, stable, high-quality nanoparticles. Better yet, all of this can be modelled and further understood using Computational Fluid Dynamics. By enabling high-throughput screening of multiple formulations at R&D and production volumes, parallel precision bioreactor arrays also accelerate the journey of LNPs from discovery to in vitro and in vivo data and into clinical trials, ultimately driving forward patient success. Add to that both the production speed and the resource efficiency – less expensive material wasted, lower costs, and better results – and it's clear why modern biotechs are adopting these systems to drive LNP production. Talk to us about either bioreactor-based or microfluidic Precision LNPs today at info@biologic.tech.com. Follow BiologIC Technologies on LinkedIn for more content about the latest advanced bioprocessing systems. #Bioprocessing #LNPs #mRNATherapies #Innovation #SmallScaleBioreactors #AdvancedTherapies

Hi fi twins: scale down models that match your GMP process...

Modern biotechnology enterprises built on precision technology platforms will move faster than ever before to improve human health and our environment. It is our responsibility to share the stories of how society will benefit from the work of our science community and also to inspire tomorrow's bioengineers who will shape the world for the better. Thank you to Janine Machin, Technology Correspondent at BBC News, for broadcasting and writing on our story so eloquently.

Imagine developing advanced medicines on the same end-to-end integrated bioprocessing platform that will both get you to clinic faster and distribute manufacture...and that our technology makes this so affordable that any startup with ambitious science can "Build on BiologIC" and control their own destiny...! Excited to work with the forward-thinking and eminent scientists at CEPI (Coalition for Epidemic Preparedness Innovations) as a part of our rapidly growing bioprocessing ecosystem.

BiologIC has partnered with UK Space Agency to adapt its precision bioprocessing platform to a configuration suitable for microgravity operation in Low Earth Orbit and space environments. Space biomanufacturing will become a strategic imperative for nations needing to sustain human activities in deep space and for biopharmaceutical companies seeking new therapeutic value from microgravity environments. Biocomputer technology promises to meet the exacting demands of extreme environments by providing robust, distributed and semi-autonomous bioprocessing infrastructure that can be reconfigured to a broad range of therapeutic and synthetic biology applications. Addressing applications in cell, gene, antibody, ADC, RNA-LNP and stem cell therapies, biocomputer technology is being rapidly adopted by modern biotechnology enterprises. The proprietary platform architecture outmodes expensive legacy hardware because it is standardised yet configurable, modular and highly integrated giving greater process robustness, flexibility and scalability. The end-to-end integrated platform enables true digitalisation of bioproduction for the age of AI. UKSA is investing £65m in ground-breaking innovations that could boost UK leadership in space technologies and applications through its National Space Innovation Programme to support projects designed by British organisations with the potential to accelerate the development of new space technologies and services. #bioprocessing #biomanufacturing #spacetechnology

BiologIC Technologies and CEPI (Coalition for Epidemic Preparedness Innovations) are collaborating on a precision mRNA-LNP bioprocessing platform to greatly accelerate time to clinic and distribute continuous vaccine manufacturing to the point of need to contain or stop disease outbreaks. Addressing applications in cell, gene, antibody, ADC, RNA-LNP and stem cell therapies, biocomputer technology is being rapidly adopted by modern biotechnology enterprises. The proprietary platform architecture outmodes expensive legacy hardware because it is standardised yet configurable, modular and highly integrated giving greater process robustness, flexibility and scalability. The end-to-end integrated platform enables true digitalisation of bioproduction for the age of AI. CEPI is backed by the Bill & Melinda Gates Foundation. Central to CEPI’s pandemic-beating five-year plan is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. #vaccines #RNAtherapy #bioprocessing

We're excited to partner with the Smart Manufacturing Data Hub to radically reduce the time and cost of manufacturing cutting edge bioprocessing devices for our leading biotechnology customers.

Our CEO Richard Vellacott was delighted to represent BiologIC Technologies at Number 10 Downing Street. He met with the government, including the science minister Andrew Griffith, Harvard Business School and Imperial College Business School to discuss entrepreneurial opportunities for science and technology businesses in the UK.

For AI to accelerate the fields of therapy and engineered biology, modern biotechnology companies must be built on robust, integrated platforms. Thank you to BBC News Technology Correspondent, Janine Machin, for sharing the real world importance of AI and how our customers are moving faster than ever using our technology-enabled products. #cellandgenetherapy #bioprocessing #nucleicacid